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OBJECTIVES: Decisions on palliative chemotherapy (CT) for advanced gastric cancer 
require trade-offs between potential benefits and risks for patients. Healthcare 
providers and payers agreed that patient preferences should be considered. We 
conducted a CBC study in patients with mGC or mGEJ-Ca from Germany to evaluate 
their preferences when trading-off between treatment tolerability, quality of life 
and survival benefit. METHODS: German oncologists were contacted to identify 
patients with mGC or mGEJ-Ca who had completed ≥ 2 cycles of palliative CT (ongo-
ing or completed). The primary objective was the quantitative evaluation of patient 
preferences for palliative CT in this population by CBC analysis. The CBC matrix, 
developed based on 6 in-depth qualitative interviews, spanned the 3 attributes 
ability to self-care as a key component for quality of life, treatment toxicity and 
survival benefit (3-4 factor levels each, 15 iterations). A minimum of 50 partici-
pants was needed. Eligible consenting patients completed the 45min standardized 
CBC-survey, choosing systematically among profiles. CBC models were estimated 
by mixed-logit regression (MLR) and hierarchical Bayes analysis (HB). Estimates of 
importance for each attribute and factor-level were calculated. RESULTS: Overall, 
55 patients participated in the survey (78% male, median age 63yrs, 82% currently 
receiving CT). Patients considered low treatment toxicity as most important (45% 
relative importance, MLR analysis), followed by ability to self-care (32%) and an 
additional survival benefit of up to 3 months (3 months 23%, 2 months 18%, 1 month 
11%). The MLR analysis showed high validity (certainty 37.9%, chi square p< 0.01, root 
likelihood 0.505). The HB analysis yielded similar results. CONCLUSIONS: Patient 
preferences related to palliative CT of gastric cancer can appropriately be assessed 
by CBC analysis. Though patients’ varied experiences with chemotherapy may have 
impacted specific responses, across the population of patients with mGC or mGEJ-Ca 
improved treatment tolerability and quality of life were ranked highest.
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OBJECTIVES: The main objective of our study was to assess the population’s 
participation in cervical smear testing and knowledge on HPV, also learn about 
women’s attitudes about the vaccine. METHODS: The quantitative cross-sectional 
questionnaire survey was performed among women in a Hungarian town, Vác in 
2013. 150 questionnaires were distributed, of which 120 proved to be evaluable. The 
study was performed with χ 2-test and t-test as a statistical method besides 95% 
probability (p< 0.05). We used SPSS version 20.0 program. RESULTS: 85.5% of the 
respondent women had cervical smear tests. 89.2% of respondent women reported 
an annual visit for screening. Their average age was 22.01±.5.8SD years when they 
first attended screening. Women participated in screening were significantly (t= 4.89, 
p< 0,001) older (36.56), than those who never took part in (26.62). Five questions in 
the survey concerned knowledge on HPV. On the basis of these questions only 27.9% 
of the women had adequate knowledge. The majority of women (80.8%) knew the 
meaning of the acronym HPV, at the same time only 29.2% of them knew that the 
infection affected “both men and women”. Concerning prevention only women 
living in marriage or cohabitation (χ 2= 20.00, p= 0.001) were significantly better 
informed on the issue than single mothers. 85% of the respondent women heard 
about the vaccination against HPV. Only 10 women of the respondents had HPV 
vaccination, and significantly more women over 34 years of age would require vac-
cination for themselves (χ 2= 9.010, p= 0.011) and their daughters (χ 2= 7.415, p= 0.006) 
than their younger counterparts. CONCLUSIONS: Women reported an extremely 
high participation rate in cervical cancer screening, however the overall awareness 
of human papillomavirus in the respondents is superficial (27.9%), therefore, their 
willingness for vaccination is not adequate. In the future, a wide range of informa-
tion should be provided for them to enhance their awareness.
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OBJECTIVES: Patient reported outcomes (PROs) have gained a prominent place in 
clinical research. Previous estimates suggest that PRO measures are used in 14% of 
clinical trials. Online registries, such as ClinicalTrials.gov, may be useful for updat-
ing the extent of PRO use. The objectives of this study were to: (1) estimate the 
proportion of clinical trials that include at least one PRO measure, and (2) examine 
associations between trial characteristics and the use of PRO measures. Particular 
emphasis was given to evaluation of use in oncology studies. METHODS: A local 
copy of the ClinicalTrials.gov database was made containing all data from November 
2007 to December 2013. Content was searched for use of PRO measures. Multivariate 
logistic regression was used to investigate possible associations between trial-level 
characteristics and use of PRO measures. RESULTS: Of 96,736 registered trials, 
25,880 (27%) were identified as using one or more PRO measure. Among oncology 
trials, 29% (3,947/13,584) were identified as using a PRO measure, compared to 26% 
(21,933/83,152) of non-oncology trials. Trials using PRO measures were more likely 
to be sponsored by university/research organizations (29%) or the US government 
(33%); Phase III (35%); randomized (32%); and evaluating devices (30%), procedures 
(32%) or behaviors (50%), compared to drugs (24%). They were less likely to be reg-
ulated by the FDA (23%). CONCLUSIONS: Between 2007 and 2013, there was an 
increase in the number of trials using a PRO measure, particularly in oncology trials. 
The increased use may be attributed, in part, to the changing landscape of patient-
centered care and stakeholder engagement in general. With recent initiatives such 
as the Patient-Focused Drug Development and the NIH-sponsored Patient-Reported 
Outcomes Measurement Information System, the use of PRO measures in clinical 
research will likely increase further.
through the inclusion of studies identified in references lists. Of these 27 stud-
ies, only one provided a statistical regression model describing a relationship 
between FACT-G and EQ-5D in individuals with malignant melanoma. While the 
analyses and data used were described appropriately and satisfied the majority of 
recommendations in the published checklist, the preference-based utility weights 
used in this study were not obtained from the UK population. CONCLUSIONS: 
This study confirms there is very little evidence which could be used to generate 
preference-based utility scores from FACT data. Although one relationship was 
identified which could be used to estimate proxy preference-based utility scores, 
it is not ideal for the UK.
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OBJECTIVES: As part of the Lilly Oncology Patient Access to Cancer care Excellence 
(PACE) initiative, the 2014 PACE Cancer Perceptions Index survey was conducted 
to identify general public perceptions of cancer and its treatment in South 
Korea. METHODS: The general public consisted of a nationally representative 
sample of 500 respondents aged ≥ 18 years who participated in telephone inter-
views initiated by random digit dialing from March 25 to April 22, 2014. Responses 
were evaluated by analysis of frequencies of responses and mean scores. RESULTS: 
Less than half (39%) of the general public expressed satisfaction with progress in 
cancer treatment, and most (82%) believe it takes too long for new cancer medi-
cines to reach patients. Most (68%) of the general public believe clinical trials offer 
patients a chance to receive better treatments than those currently available, and 
the majority (82%) would be willing to participate in a clinical trial if they might 
receive a life-extending treatment. Most of the general public strongly agreed on 
the need for coordination of efforts across national borders (96%), and greater col-
laboration among government, academic institutions, non-profit organizations, 
and pharmaceutical companies (96%), in the development of new cancer medi-
cines. CONCLUSIONS: The general public in South Korea is ambivalent toward 
overall progress in the fight against cancer, and impatient with the pace of pro-
gress. Despite some differences in perceptions in South Korea compared to those 
previously published for PACE surveys in the United States, France, Germany, Italy, 
Japan, and the United Kingdom, the general public in South Korea is consistent 
with the general public in the other six countries in identifying cancer as a health 
priority, and wanting greater investment in addressing the disease as well as faster 
availability of new medicines.
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OBJECTIVES: Studies designed to assess the psychosocial factors affecting 
patients with mCRPC are sparse. Understanding this area may help patients 
and their caregivers communicate and make informed treatment decisions 
with their physicians. We used qualitative research methods to explore patient, 
caregiver, and physician experiences with oral oncolytic therapy. METHODS: 
Our ecological approach postulates that patient, caregiver, and physician treat-
ment decisions and experiences around mCRPC can result from multiple factors 
impacting individuals via social, organizational, community, governmental pol-
icy, and economic influences. Interview guides were developed and tested using 
core concepts of the ecological health model, and conducted with three relevant 
stakeholder groups: 30 patients with mCRPC, 26 caregivers, and an independent 
sample of 30 physicians (oncologists and urologists) who actively treat mCRPC. 
Patients and physicians were identified from a national claims database and car-
egivers were nominated by consented patients. Demographic information was 
collected on patients. Interviews were approved by an Independent Institutional 
Review Board. Interview responses were coded into QSR-NVIVO-10 software and 
analyzed using grounded theory. RESULTS: The majority of patients were age ≥ 70 
years and Caucasian. Patients were taking either abiraterone acetate (32%) or enza-
lutamide (48%). Spouses were the predominant caregiver (89%). Physician specialty 
was stratified into oncologists (77%) and urologists (23%). Six major themes were 
identified: relationship with physicians; effects of disruptions to patients’ physical 
and social activities; communication with physicians; access to the medications; 
role of attitudes in coping with CRPC; and supports and communication. All stake-
holders cited financial factors impacting access to treatment. CONCLUSIONS: There 
were different perspectives on the primary concerns around mCRPC, with patients 
citing loss of social functioning, caregivers fearing that patients would die, and 
physician citing pain. By improving understanding of these experiences, opportuni-
ties exist to improve treatment-related decisions for patients with mCRPC. These 
findings can also inform future quantitative population-based studies.
PCN115
PatieNt PrefereNCeS for Palliative treatmeNt of loCally advaNCed 
or metaStatiC gaStriC CaNCer aNd adeNoCarCiNoma of tHe 
gaStrooeSoPHageal JuNCtioN: a CHoiCe-BaSed CoNJoiNt aNalySiS 
Study from germaNy
Hofheinz R.1, Clouth J.2, Borchardt-Wagner J.2, Wagner U.2, Weidling E.2, Jen M.3, Brueck P.2
1University Hospital Mannheim, Mannheim, Germany, 2Lilly Deutschland GmbH, Bad Homburg, 
Germany, 3Eli Lilly and Company, Surrey, UK
A210  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
of the 61 CIs confirmed that the draft SSA was interpreted as intended by patients, 
and assesses concepts relevant to and experienced by patients across all examined 
cancer types. Minor revisions were made to nine items to improve clarity. One 
additional item was added to ensure comprehensiveness. CONCLUSIONS: The SSA 
demonstrates strong content validity, assessing relevant CaF concepts in a man-
ner patients understand. Planned future development activities include additional 
CIs to confirm content validity of the revised, 14-item SSA in an electronic format, 
followed by an observational study for the development of scoring, item reduction, 
and psychometric validation.
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OBJECTIVES: To assess frequency and type of Patient-Reported Outcomes (PROs) in 
studies of bladder cancer. METHODS: A search of Citeline’s Trialtrove was conducted 
using the search criteria “Bladder Cancer” as the disease, drugs tested was “any”, 
trial phase was II/III, III, and IV, and included planned, ongoing and completed stud-
ies. This resulted in 182 trials. Study design included clinical trials (double-blind, 
open-label) and observational studies. Start dates ranged from 1985-2014. Trials 
were excluded if disease type was other than bladder cancer. The remaining 138 
trials were reviewed to determine prevalence and type of PROs. RESULTS: Only 
27 (7.4%) of the studies included PROs as stated in the endpoints section despite 
bladder cancer being one of the most commonly diagnosed types of cancer in the 
US, especially among men. For these 27 trials, 9 different PROs were identified, 3 of 
which were bladder cancer disease specific. A total of 39 PROs were included with a 
range of 1-2 PROs per study, an average of 1.44 PROs. Thirty-four (87%) of these PROs 
measured Health-Related Quality of Life (HRQL) and 5 (13%) were symptom-based 
measures. Within the HRQL measures, 9 (26.5%) were cancer general, 9 (26.5%) were 
specific to Bladder Cancer, 1 (3%) was generic (e.g., SF-36), and the remaining 15 
(44%) were not specified. Among the symptom measures, 3 (60%) were specific to 
bladder cancer and 2 (40%) were generic. CONCLUSIONS: Results indicate that the 
prevalence of PROs in bladder cancer trials is low compared to other cancers (e.g., 
ovarian cancer) and other diseases despite their importance in evaluating impact 
of disease and treatment benefit. The type of PRO most commonly indicated was a 
bladder cancer disease-specific measure of HRQL. Findings show the need to high-
light the value and relevance of patient-reported data to increase incorporation of 
PROs in bladder cancer trials.
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OBJECTIVES: To assess use of Patient-Reported Outcomes (PROs) in studies of 
Ovarian Cancer. METHODS: A search of Citeline’s Trialtrove was conducted using 
the search criteria of “Ovarian Cancer” as the disease, drugs tested was “any,” and 
trial phase was II/III, III, and IV. This resulted in 252 trials. Studies were excluded 
if the disease type was other than ovarian cancer. Study designs were clinical trial 
and observational studies, and both double-blind and open-label studies were 
included. Target accrual for all studies was ≥ 53. Start dates ranged from 1990 
to 2014. The remaining 189 trials were then assessed for prevalence and type of 
PROs. RESULTS: Of the 189 studies reviewed, 102 (54%) included PROs. For these 
102 trials, a total of 148 PROs were included, and an average of 1.5 PROs were 
used per study with a range of 1 to 4. A total of 15 different PROs were identified. 
One hundred twenty-six (85%) of these PROs measured Health-Related Quality of 
Life (HRQL), 10 (7%) measured QoL/Utilities, 9 (6%) measured Symptoms, 2 (1%) 
measured Activities of Daily Living and 1 (1%) was categorized as other. Within 
the HRQL measures, 35 (28%) were ovarian cancer specific measures, 27 (21%) 
were cancer general measures, 6 (5%) were cancer treatment specific, 2 (2%) were 
generic measures and 1 (1%) was chemotherapy treatment specific. The remaining 
55 (43%) HRQL endpoints were unspecified. CONCLUSIONS: PROs are included in 
ovarian cancer clinical studies approximately half the time, which is low compared 
to other disease areas. The majority of measures assess HRQL and are specific to 
ovarian cancer. Including HRQL in ovarian cancer studies can support the value of 
progression free survival to patients. PROs can be used to show the value of new 
ovarian cancer drug therapies.
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OBJECTIVES: The EORTC QLQ-C30 is a validated patient reported outcome measure 
for cancer patients but there is limited evidence on its validity in Myelofibrosis 
(MF), a rare but serious bone-marrow cancer. This study aimed to provide evi-
dence of its validity in MF. METHODS: QLQ-C30 was compared to MF specific 
measures (MF-SAF 2.0 and FACT-Lym) using trial data of MF patients (COMFORT I 
(n= 309) and COMFORT II (n= 219)). Convergent validity based on correlation analy-
sis, known group analysis based on MF specific measures using Cohen’s d effect 
size (ES) and responsiveness based on standardised response mean (SRM) were 
undertaken. RESULTS: QLQ-C30 dimensions (physical, role, emotional and social 
functioning, pain and fatigue) were strongly correlated (ρ > 0.5) with equivalent 
items/dimensions in the MF-SAF and FACT-Lym but all QLQ_C30 dimensions were 
weakly correlated (ρ < 0.3) to MF symptoms such as weight loss, itching and night 
sweats. Most QLQ-C30 dimensions were able to discriminate between MF-SAF 
(scores 0-10; 11-20; 21-30; 31-60) with better discrimination for the mild severity 
low score groups (0.2< ES< 0.7) compared to high score groups (ES< 0.2) who had 
higher severity and the FACT-Lym (scores 0-30; 31-40; 41-50; 51-60) groups. SRMs 
were < 0.2 for most QLQ-C30 dimensions including pain but > 0.2 for MF-SAF and 
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OBJECTIVES: Taste dysfunction is a common, debilitating problem for head and 
neck cancer treatment survivors (HNCTS). When taste is impaired eating is not as 
enjoyable, appetite is diminished and overall health related quality of life (HRQoL) 
is diminished. However, the extent to which taste impairment in HNCTS remains 
altered over time is not well understood. METHODS: The Ovid MEDLINE®, SCOPUS, 
and CINAHL data bases were searched for reports of HNCTS in which taste function 
was measured. Eligible studies compared taste scores baseline to up to five years 
post treatment. 3872 reports were identified in the literature search and 20 studies 
were suitable for inclusion in the final analysis. Estimates of effect size of head 
and neck cancer therapy on taste dysfunction were extracted from each study. 
A descriptive meta-analysis was conducted using Comprehensive Meta-analysis 
software (Version 2, Biostat, Englewood, NJ). RESULTS: The meta-analysis included 
data on 1526 subjects. The sample was predominantly young in age (mean age is 
59.11 years) and 66.8% male. Head and neck cancer treatment survivors reported 
statistically significantly worse taste scores 6 months or longer after completing all 
cancer treatment. The summary effect for the standard measure difference between 
pretreatment and post-treatment taste scores was 0.331 (p= < 0.001). The sample 
was highly heterogeneous in terms of country, tumor site, and therapy, so a random 
effects model was chosen for data analysis. Heterogeneity testing supported this 
decision (Q= 82.08, df 18, p < 0.001). CONCLUSIONS: Assessment of HRQoL in HNCTS 
should include questions on taste function. With the global increase in HPV related 
head and neck cancers, the pool of treatment survivors is expected to increase over 
the next decade. The Taste dysfunction is a long-term complication for HNCTS and 
clinicians should screen survivors for this sensory dysfunction.
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OBJECTIVES: The US Food and Drug Administration (FDA) did not approve any 
PRO label claims for cancer treatments between 2006 and 2010. In December 2009, 
the agency published guidance on the use of PROs to support label claims, and 
in 2012 the Center for Medical Technology Policy (CMTP) called for all prospec-
tive comparative studies of oncology drugs in adults to include PRO measures. 
The current study sought to identify how many PRO claims have been approved 
since the publication of these documents, to consider the challenges for sponsors 
seeking such claims, and offer solutions to these challenges. METHODS: The FDA 
website was searched for approvals of hematology and oncology drugs 2010–2014. 
The most recently approved labels of eligible products and drug approval packages 
were reviewed for comments on PRO data. RESULTS: Of 64 drug labels suitable 
for review, two had PRO efficacy claims: ruxolitinib (myelofibrosis) was claimed to 
improve symptoms, as measured by the Myelofibrosis Symptom Assessment Form; 
abiraterone acetate (prostate cancer) was claimed to improve pain, as measured 
by the Brief Pain Inventory (BPI-SF). For crizotinib (NSCLC), PROs were used to sup-
port adverse event reporting (vision disorders). The label for brentuximab stated 
that no improvement in patient-reported symptoms for either indication (Hodgkin 
lymphoma and anaplastic large cell lymphoma) had been established. A further 
12 labels stated that there were no data to demonstrate improvement in disease-
related symptoms. CONCLUSIONS: This review demonstrates the emergence of 
PRO label claims for oncology products, despite the recent FDA and CMTP guidance 
PRO data are infrequently documented in FDA-approved oncology labels. Labels 
increasingly specify when there is an absence of symptom data e.g. brentuximab, 
carfilzomib, marking a shift in FDAs expectations. Sponsors face challenges such as 
a lack of validated tumor-specific instruments. A strategic four-step PRO endpoint 
development process provides a way forward.
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OBJECTIVES: Cancer-related fatigue (CaF) is a common symptom of cancer and one 
that can be burdensome to patients. It is possibly under-reported due to its complex 
origins, inconsistent definitions and assessment methods. In recent years, no exist-
ing measures have been accepted by the US Food and Drug Administration (FDA) to 
support labeling claims in CaF. The Patient-Reported Outcomes of Fatigue in Cancer 
(PROOF-C) Consortium have developed the Symptom Severity Assessment (SSA), a 
patient-reported outcome (PRO) measure of CaF to be aligned with FDA expectations 
as part of the FDA’s Drug Development Tool (DDT) Qualification Program. METHODS: 
In total 91 open-ended concept elicitation (CE) interviews were conducted among 
eight cancer types to spontaneously elicit the patient experience of CaF. Items 
were generated based on qualitative, thematic analysis of verbatim transcripts and 
with input from a clinical expert. Subsequently, 61 cognitive interviews (CIs) were 
conducted with patients in six cancer types, wherein a “think-aloud” process and 
targeted debriefing questions were used to assess concept relevance and patients’ 
understanding of the instructions, items, and response options. RESULTS: CE data 
supported the development of a draft, 13-item SSA, measuring eight symptoms of 
CaF, with a 24-hour recall period and an 11-point numeric rating scale. The results 
